Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — FY2024 Earnings Presentation
11 slides from Viemed Healthcare's earnings presentation, Mar 10, 2025
Slide 1: Financial Supplement: Fourth Quarter & Full Year 2024
Financial Supplement NASDAQ: VMD Leading th e Healthcare Industry in Home Respiratory Care March 10, 2025 1 Fourth Quarter & Full Year 2024
Slide 2: Disclaimers: Forward Looking Statements
Disclaimers Forward Looking Statements Certain statements contained in this Financial Supplement may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian
Slide 3: Key Themes for Q4 2024 and FY 2024
Key Themes for Q4 2024 and FY 2024 3 We have increased the population we can serve for non-invasive ventilation, sleep, staffing, and other complementary services by diversifying our business and product mix through organic and inorganic growth. A significant underserved population still remains for
Slide 4: Financial and Operational Highlights
Financial and Operational Highlights 4 (expressed in thousands of U.S. Dollars, except operational information). (1) Refer to "Non-GAAP Reconciliations" in this presentation for definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure. (2) Vent Patients represents the n
Slide 5: Service, Payor and Revenue Mix
Ventilation 56% Sleep 16% Oxygen 11% Other 17% Service, Payor and Revenue Mix 5 Medicare 41% Medicaid /MCO 7% Medicare Advantage 21% Commercial 18% Other 13% Rental 77% Sales 23% SERVICE MIX FY 2024 PAYOR MIX FY 2024 REVENUE MIX FY 2024 VieMed Healthcare Inc. I Supplemental Presentation
Slide 6: Net Revenue Highlights
Net Revenue Highlights 6 For the quarter ended 12/31/24 9/30/24 6/30/24 3/31/24 12/31/23 9/30/23 6/30/23 3/31/23 Rental Revenue (expressed in thousands of USD): Ventilators, non-invasive & invasive $33,173 $31,772 $30,445 $29,187 $29,077 $28,322 $25,712 $25,147 Other HME equipment rentals $13,047 $1
Slide 7: Free Cash Flow
Free Cash Flow 7 For the year ended 12/31/24 12/31/23 12/31/22 Net cash provided by operating activities 39,089 45,212 27,748 Less: Purchase of property and equipment 37,771 26,093 22,898 Proceeds from sale of property and equipment (10,321) (2,588) (1,063) Net CAPEX 27,450 23,505 21,835 Free Cash F
Slide 8: Liquidity Metrics
Liquidity Metrics 8 Positioned for growth • The Company maintains a healthy balance sheet with no net debt as of December 31, 2024, providing significant financial flexibility. • As of December 31, 2024, the Company has $55 million in unfunded commitments available under its existing credit faciliti
Slide 9: 2025 Guidance – Commentary
2025 Guidance – Commentary 9 • Leaning into what worked well throughout 2024 with a focus on organic growth • Ramping up the sales force at a more aggressive pace based on success of restructuring and infrastructure put in place in 2024 • Expecting continued growth in staffing due to unique position
Slide 10: 2025 Guidance – Commentary Core Metrics
2025 Guidance – Commentary 10 Core Metrics • Net revenue of $254 million to $265 million • Adjusted EBITDA of $54 million to $58 million (21%-23% of net revenue) Directional Commentary on Quarterly Cadence • Year-over-year growth expected to be consistent with prior year • Q1 is typically flat to do
Slide 11: Non-GAAP Reconciliations
Non-GAAP Reconciliations 11 (a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impa